In a report released yesterday, Andrew D’silva from B.Riley FBR maintained a Buy rating on CryoPort Inc (CYRX), with a price target of $22. The company’s shares opened today at $10.04.
D’silva noted:
“We derive our $22 price target by assigning a 7x EV/sales multiple to our 2022 revenue estimate of $143.2M, which we discount by 15% annually to 2019.”
According to TipRanks.com, D’silva is a 3-star analyst with an average return of 2.5% and a 34.9% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Imprimis Pharmaceuticals, and Oramed Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CryoPort Inc with a $18.33 average price target.
See today’s analyst top recommended stocks >>
Based on CryoPort Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $2.14 million. In comparison, last year the company had a GAAP net loss of $1.98 million.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Lake Forest, CA.
